Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) FCF Margin (2022 - 2025)

Historic FCF Margin for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to 10272906339.26%.

  • Addex Therapeutics' FCF Margin fell 121810576858500.0% to 10272906339.26% in Q2 2025 from the same period last year, while for Sep 2025 it was 4662902372.29%, marking a year-over-year increase of 43391434421000.0%. This contributed to the annual value of 1330.07% for FY2024, which is 8341300.0% down from last year.
  • As of Q2 2025, Addex Therapeutics' FCF Margin stood at 10272906339.26%, which was down 121810576858500.0% from 663717088.85% recorded in Q1 2025.
  • Addex Therapeutics' 5-year FCF Margin high stood at 354689630316.51% for Q4 2024, and its period low was 10272906339.26% during Q2 2025.
  • For the 4-year period, Addex Therapeutics' FCF Margin averaged around 24148952653.53%, with its median value being 2610.95% (2022).
  • As far as peak fluctuations go, Addex Therapeutics' FCF Margin soared by 2000000000bps in 2024, and later crashed by 2000000000bps in 2025.
  • Quarter analysis of 4 years shows Addex Therapeutics' FCF Margin stood at 518.71% in 2022, then skyrocketed by 925140749bps to 4798758561.85% in 2023, then skyrocketed by 7291bps to 354689630316.51% in 2024, then plummeted by -103bps to 10272906339.26% in 2025.
  • Its FCF Margin was 10272906339.26% in Q2 2025, compared to 663717088.85% in Q1 2025 and 354689630316.51% in Q4 2024.